Clinical Studies
Blood Lipid Lowering Activity and Related Effects
Study 1
Phase II Clinical Studies conducted in India as shown below
Figure 16
Effect of Gugulipid on serum cholesterol levels of hyperlipidemic patients.
Figure 17
Effect of Gugulipid on the serum lipids of 7 patients with ischemic heart disease.
Figure 18
Effect of Gugulipid on serum lipids of 39 patients without ischemic heart disease.
Figure 19
Effect of Gugulipid on the HDL, LDL, and VLDL of patients without IHD.
Figure 20
Effect of Gugulipid on the HDL, LDL, and VLDL of patients with IHD.
Figure 21
Effect of Gugulipid on the serum cholesterol levels of hyperlipidemic patients.
Study 2
Objective: To study the effect of gum guggul on the serum fibrinolytic activity (FA) and platelet adhesive index (PAI).
Methods: Healthy subjects (20) and patients of coronary heart disease were divided into control and treated subgroups. The treated groups received a gum guggul fraction of 0.5 g twice daily in a gelatin capsule for 30 days. Withdrawn blood samples were analyzed for fibrinolytic activity and platelet adhesive index.
Results
Figure 22
Effect of gum guggul on the fibrinolytic activity of healthy subjects.
Figure 23
Effect of gum guggul on the fibrinolytic activity of CAD patients.
Figure 24
Effect of gum guggul on the platelet adhesive index in healthy subjects.
Figure 25
Effect of gum guggul on the platelet adhesive index in CAD patients.
Conclusions: The gum guggul fraction reduced platelet adhesiveness and increased the blood’s fibrinolytic activity (i.e. fibrin-breaking activity), two actions that are extremely beneficial in protecting against heart attack and stroke (thrombosis). The activity persisted as long as the gum guggul was taken.
